Hikaru Fujita, Sachiko Arai, Hiroshi Arakawa, Kana Hamamoto, Toshiyuki Kato, Tsubasa Arai, Nanaka Nitta, Kazuki Hotta, Natsuko Hosokawa, Takako Ohbayashi, et al. Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers. Bioorg Med Chem . 2024. 102. 117674
Yoshihiro Watanabe, Natsuko Hosokawa, Misaki Yoshida, Tomoyuki Miura, Mitsuhiro Kawano. Identification of Closed Linear Epitopes in S1-RBD and S2-HR1/2 of SARS-CoV-2 Spike Protein Able to Induce Neutralizing Abs. Vaccines. 2023. 11. 2
Paing Linn, Susumu Kohno, Jindan Sheng, Nilakshi Kulathunga, Hai Yu, Zhiheng Zhang, Dominic Voon, Yoshihiro Watanabe, Chiaki Takahashi. Targeting RB1 Loss in Cancers. Cancers. 2021. 13. 15. 3737-3737
Shinji Sakamoto, Mika Kirinashizawa, Yumi Mohara, Yoshihiro Watanabe. Generation and characterization of monoclonal antibodies against mature hepcidin and its application to neutralization and quantitative alteration assay. Bioscience, Biotechnology, and Biochemistry. 2021. 85. 2. 340-350
Susumu Kohno, Paing Linn, Naoko Nagatani, Yoshihiro Watanabe, Sharad Kumar, Tomoyoshi Soga, Chiaki Takahashi. Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion. Oncogene. 2020. 39. 34. 5690-5707
Identification of Neutralizing Ab-epitopes in SARS CoV-2 S Antigen and Their Utilization
(8th International Conference on Vaccines Research & Development. 2023)
Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy
(American Society of Hematology, 2019. 2019)
Clinical Success Story "Discovery of Trametinib as a MEK Inhibitor able to alter Phosphorylation state of MEK"
(Keystone Symposia "Phenotypic Drug Discovery" 2019)